Emmaus Life Sciences is a predictive analytics company. Co. employs a platform to support personalized care for mental health patients. Co. utilizes its machine learning, artificial intelligence, data analytics platform for the delivery of telebehavioral health services and its Psychiatric Electroencephalograms (EEGs) Evaluation Registry (PEER) predictive analytics product offering. Co.'s platform (PEER Online) utilizes algorithms to analyze EEGs to generate PEER Reports to predict individual responses to a range of medications prescribed for the treatment of behavioral disorders including depression, anxiety, bipolar disorder, post-traumatic stress disorder and other non-psychotic disorders. The EMMA YTD return is shown above.
The YTD Return on the EMMA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether EMMA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EMMA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|